Current Coverage Status
Not Yet FDA-Approved
VK2735 is currently in Phase 3 clinical trials and is not available by prescription. Insurance coverage is not applicable until after FDA approval, which is projected for 2028-2029.
Until FDA approval, the only way to access VK2735 is through clinical trial participation in the VANQUISH program.
Post-Approval Coverage Outlook
When VK2735 is eventually FDA-approved, coverage will depend on several factors:
Coverage Challenges
- Late market entry: VK2735 will enter a market with established competitors (Zepbound, Wegovy, potentially CagriSema). Payers may require step therapy through existing options first.
- Viking's size: As a small biotech without existing commercial infrastructure, Viking may have less negotiating power with payers compared to Eli Lilly or Novo Nordisk.
- Obesity medication exclusions: Many insurance plans still exclude or heavily restrict obesity medications.
- Medicare Part D: By law, basic Part D coverage excludes drugs used for weight loss, unless the drug is also approved for another use (like diabetes). VK2735 is not a Medicare GLP-1 Bridge drug.
Potential Coverage Advantages
- Rapid efficacy: 14.7% weight loss at 13 weeks[4] could position VK2735 as a fast-acting option for patients who need quick results
- Monthly maintenance potential: If confirmed, less frequent dosing could reduce overall treatment costs
- Type 2 diabetes indication: If VANQUISH-2 succeeds and VK2735 is approved for T2D, Medicare Part D coverage becomes possible
- Competition benefits: More market options could drive down prices across the category
Expected Pricing
No pricing has been announced for VK2735. Based on the competitive landscape:[1]
| Drug | List Price | Notes |
|---|---|---|
| Wegovy (semaglutide) | ~$1,349/month | Established GLP-1 for obesity |
| Zepbound (tirzepatide) | ~$1,060/month | Dual GLP-1/GIP agonist |
| VK2735 (projected) | $1,000-1,300/month | Analyst estimates |
Pricing strategy considerations: Viking may price aggressively to gain market share against established competitors, or price at parity to maximize revenue. As a smaller company, Viking has less leverage but may be more willing to negotiate with payers.
Future Access Strategies
Current Access (Pre-Approval)
- Clinical trials: VANQUISH-2 may still be enrolling through Q1 2026
- No commercial access: VK2735 cannot be purchased or prescribed
Post-Approval Access (2028+)
- Patient assistance programs: Viking will likely offer co-pay assistance and income-based programs
- Prior authorization: Expect to need documentation of obesity, failed diet/exercise, and potentially failed other medications
- Appeals process: If initially denied, work with your physician to document medical necessity and appeal
- Alternative coverage: Some employer plans offer better obesity medication coverage than individual plans
FAQs
Coverage is uncertain and won't be determined until after FDA approval (projected 2028-2029). Based on current obesity medication coverage patterns, expect significant variation by plan. Many commercial plans exclude or restrict obesity medications, and by law basic Medicare Part D coverage excludes drugs used for weight loss unless VK2735 is also approved for another use, such as diabetes.
No pricing is available yet. Analysts estimate VK2735 could cost $1,000-1,300/month based on comparable drugs (Zepbound ~$1,060/month, Wegovy ~$1,349/month). Patient assistance programs will likely be available to reduce costs for eligible patients.
This is possible and would affect coverage access. Options include:
- Partnership: License VK2735 to a larger company (e.g., Pfizer, AstraZeneca) for commercialization
- Acquisition: A larger company could acquire Viking outright
- Independent launch: Viking could build its own commercial team
A partnership with a larger company could improve payer access and patient support programs.
By law, basic Medicare Part D coverage excludes drugs used for weight loss, and VK2735 is not a Medicare GLP-1 Bridge drug. However, if VK2735 is approved for type 2 diabetes (based on VANQUISH-2 trial), it could qualify for Medicare coverage for that indication. The Treat and Reduce Obesity Act, if passed, could also expand Medicare coverage for obesity medications—but passage is not guaranteed.
Sources & References
- GoodRx. GLP-1 Pricing Data. 2025. https://www.goodrx.com
- Kaiser Family Foundation. "A New Use for Wegovy Opens the Door to Medicare Coverage." 2024. https://www.kff.org/medicare/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/
- Viking Therapeutics. Investor Relations & Corporate Presentations. 2025. https://ir.vikingtherapeutics.com
- Viking Therapeutics. "Positive Top-Line Results from Phase 2 VENTURE Trial." February 2024. https://ir.vikingtherapeutics.com/news-releases
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.